Monitor Corporation’s AI Lung Cancer Solution Designated as “New Health Technology with Deferred Evaluation” — Industry First

Monitor Corporation’s AI lung cancer diagnostic solution, MONCAD LCT (know as LuCAS plus in South Korea), has been officially designated as a “New Health Technology with Deferred Evaluation” by the National Evidence-based Healthcare Collaborating Agency (NECA)—marking the first time a lung cancer solution using chest CT analysis has received this status in Korea.

This designation allows MONCAD LCT to be used in Korean medical institutions as a non-reimbursed service supporting faster clinical adoption and broader access. The AI-powered solution automatically analyzes chest CT scans to assist radiologists in early lung cancer detection and efficient diagnosis.

Currently deployed at over 100 hospitals across Korea, MONCAD LCT has also been designated an innovative medical device by the Korean Ministry of Food and Drug Safety. Monitor Corporation is now expanding its reach into Japan through a strategic partnership with Doctor Net, with more hospitals expected to adopt the technology from Q2 2025.

This milestone reinforces Monitor’s commitment to delivering impactful, clinically proven AI solutions.